ImpediMed and Mayo Clinic have joined together in a three-year development agreement to develop new solutions for the fluid status and body composition…

Samsung’s Strategy and Innovation Center has teamed with Nestlé’s Institute of Health Sciences to develop a digital health platform that would give consumers…

Illumina, a global player in the gene sequencing and array-based technologies, named Apple executive Philip Schiller to its board of directors.

Adaptimmune has become one of the first firms to have a drug accepted into EMA’s PRIME regulatory fast-track initiative.

Gene editing biotech Editas Medicine has signed a three-year R&D collab deal with Milan-based San Raffaele Telethon Institute for Gene Therapy to develop…

Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this…

Should it stay or should it IPO? That’s the question facing inVentiv owner Thomas H. Lee Partners as it weighs up potential bids from two buyout firms--while…

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…